Abstract Cisplatin-based chemotherapy combined with bevacizumab (CB) remains the standard first-line treatment for advanced or recurrent cervical cancer, integrating cytotoxic and anti-angiogenic mechanisms to improve clinical outcomes. However, treatment success is frequently undermined by dose-dependent nephrotoxicity caused by cisplatin and bevacizumab-induced vascular alterations. Thus, strategies capable of safeguarding renal function without attenuating antitumor activity are urgently needed to optimize treatment durability and patient survival. We previously developed 31c, a novel dual inhibitor of prolyl hydroxylase domain-containing protein 2 (PHD2) and histone deacetylases (HDACs), as a nephroprotective agent. Therefore, we evaluated the nephroprotective potential of 31c in a HeLa xenograft mouse model. Mice were treated with cisplatin, bevacizumab, or their combination, with or without 31c. Tumor growth kinetics and body weight were monitored to assess therapeutic response and systemic toxicity. Renal function was examined through blood urea nitrogen (BUN), serum creatinine (Scr), and erythropoietin (EPO) levels. Kidney tissues underwent histopathological evaluation using hematoxylin and eosin (H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 291.
Chen et al. (Fri,) studied this question.